Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTO dose-escalation study in neovascular age-related macular degeneration
ACTRN12612001130853Phase 2Not yet recruiting
- Sponsor
- Tactical Therapeutics
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of carboxyamidotriazole orotate in exudative macular degeneration (3 cohorts), sponsored by Tactical Therapeutics. Primary endpoints: Safety, tolerability, and pharmacokinetics of oral CTO and Prevention of vision loss. Planned start Dec 2012; status: not yet recruiting.
02
Drugs
carboxyamidotriazole orotate
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12612001130853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001130853.